Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality.
Mesa
Ruben A
RA
Hanson
Curtis A
CA
Ketterling
Rhett P
RP
Schwager
Susan
S
Knudson
Ryan A
RA
Tefferi
Ayalew
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002882:Chromosomes, Human, Pair 13 / Q000235:genetics*; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000235:genetics; D055728:Primary Myelofibrosis / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D012189:Retrospective Studies; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014314:Trisomy
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide